SK Biopharmaceuticals shifts to red in 2022 due to ... - Yonhap News Agency
| 326030 Stock | 102,100 1,500 1.45% |
About 61% of Sk Biopharmaceutica's investor base is looking to short. The analysis of current outlook of investing in Sk Biopharmaceuticals Co suggests that many traders are alarmed regarding Sk Biopharmaceutica's prospects. The current market sentiment, together with Sk Biopharmaceutica's historical and current headlines, can help investors time the market. In addition, many technical investors use Sk Biopharmaceuticals stock news signals to limit their universe of possible portfolio assets.
326030 |
SK Biopharmaceuticals shifts to red in 2022 due to ... Yonhap News Agency
Read at news.google.com
 |
Sk Biopharmaceutica Fundamental Analysis
We analyze Sk Biopharmaceutica's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sk Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sk Biopharmaceutica based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Sk Biopharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sk Biopharmaceutica stock to make a market-neutral strategy. Peer analysis of Sk Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Sk Biopharmaceutica by comparing valuation metrics with similar companies.
Peers
Sk Biopharmaceutica Related Equities
Complementary Tools for 326030 Stock analysis
When running Sk Biopharmaceutica's price analysis, check to measure Sk Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sk Biopharmaceutica is operating at the current time. Most of Sk Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sk Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sk Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sk Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |